Back    Zoom +    Zoom -
<Research>BofAS Keeps Buy Rating on CHINA LIFE (02628.HK), Expects 1Q NBV to Grow 20-30%
Recommend
28
Positive
35
Negative
24
CHINA LIFE (02628.HK)'s 2025 net profit rose 44%YoY, BofA Securities issued a research report saying. In 4Q25, due to a significant QoQ decline in investment income and lower insurance service revenue, the Company recorded a net loss of RMB13.7 billion.

The broker expected CHINA LIFE's 1Q26 new business value to grow by 20-30%. However, due to the Company's aggressive investment strategy, BofA Securities anticipated a YoY decline in net profit, but believed that short-term fluctuations in investment income should not affect its forecasts for the Company's long-term and normal investment returns.

Related News CICC Notes Significant Improvement in China Life (02628.HK) New Business Liability Guarantee Costs, Maintains 'Outperform' Rating
BofA Securities raised its 2026 earnings forecast for CHINA LIFE by 5%, but lowered its 2027 earnings forecast by 1%. The broker kept its target price/ rating for CHINA LIFE's H-shares at $33.1/ Buy.
AASTOCKS Financial News
Website: www.aastocks.com